← Back to Search

Other

MC-1101 active for Age-Related Macular Degeneration (McCP2/3 Trial)

Phase 2 & 3
Waitlist Available
Led By Mitchell J Goff, MD
Research Sponsored by MacuCLEAR, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months

Summary

This trial is testing eye drops called MC-1101 on patients with a specific type of age-related vision problem. The goal is to see if these drops can improve blood flow in the eye and help with their condition.

Eligible Conditions
  • Age-Related Macular Degeneration

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Visual Function
Secondary study objectives
Safety and tolerability (incidence and severity of adverse events, ocular irritability, ocular hyperemia)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MC-1101 activeExperimental Treatment1 Intervention
Topical Drug 1% Ophthalmic Solution Topically, two times per day; morning and bedtime
Group II: MC-1101 Vehicle ControlPlacebo Group1 Intervention
Topical Drug: Ophthalmic Solution Topically, two times per day; morning and bedtime
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MC-1101
2009
Completed Phase 1
~40

Find a Location

Who is running the clinical trial?

MacuCLEAR, Inc.Lead Sponsor
3 Previous Clinical Trials
73 Total Patients Enrolled
Mitchell J Goff, MDPrincipal InvestigatorRocky Mountain Retina Consultants
~5 spots leftby Dec 2025